Clinical Research

Drug Development Regulatory Affairs Drug Approval Trial Results AstraZeneca Collaboration Agreements Collaboration Drug Approval Process Funding Innovation Innovative Treatments Biopharmaceutical Companies Novo Nordisk Market Impact Partnerships Market Competition Product Launch Stock Market Market Trends

5 ARTICLES

last mo.

Viking’s VK2735 Shows Durable Weight Loss With Less‑Frequent Dosing

Top‑line maintenance data point to every‑other‑week and monthly schedules that could boost patient adherence while investors await longer follow‑up to judge a commercial edge.

9 ARTICLES

2mo ago

Avalo Therapeutics Reports Positive Phase 2 HS Results, Prices $375 Million Offering

3 ARTICLES

7mo ago

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

5 ARTICLES

8mo ago

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

3 ARTICLES

10mo ago

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

3 ARTICLES

11mo ago

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

4 ARTICLES

11mo ago

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

5 ARTICLES

11mo ago

Belite Bio’s Tinlarebant Cuts Stargardt Lesion Growth 36% in Phase 3 Trial

3 ARTICLES

last yr.

AstraZeneca’s Baxdrostat Lowers 24-Hour Systolic BP by 14 mmHg in Phase 3, AHA Presentation Confirms

6 ARTICLES

last yr.

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

4 ARTICLES

last yr.

Harvard Team Releases PDGrapher, an AI to Predict Gene and Drug Combos That Reverse Diseased Cell States

3 ARTICLES

last yr.

Jaypirca Delivers Significant PFS Benefit Over Chemoimmunotherapy in First-Line CLL/SLL

3 ARTICLES

last yr.

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex

Clinical Research

Viking’s VK2735 Shows Durable Weight Loss With Less‑Frequent Dosing

AI-Designed Drug Rentosertib Lowers Biological-Age Signals in Small Trial

EyePoint Stock Collapses After Duravyu Misses Phase 3 Primary Endpoint

Purified THC‑CBD Drug Cuts Agitation in End‑of‑Life Dementia, Trial Shows

Avalo Therapeutics Reports Positive Phase 2 HS Results, Prices $375 Million Offering

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Never miss stories about

Clinical Research

Belite Bio’s Tinlarebant Cuts Stargardt Lesion Growth 36% in Phase 3 Trial

AstraZeneca’s Baxdrostat Lowers 24-Hour Systolic BP by 14 mmHg in Phase 3, AHA Presentation Confirms

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Harvard Team Releases PDGrapher, an AI to Predict Gene and Drug Combos That Reverse Diseased Cell States

Jaypirca Delivers Significant PFS Benefit Over Chemoimmunotherapy in First-Line CLL/SLL

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex

Never miss stories about

Clinical Research